You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 129 No. 2, February 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Head & Neck Cancer
 •Neoplasms of Head & Neck
 •Pathology of Head & Neck
 •Skull Base Procedures
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Urokinase-Type Plasminogen Activator Receptor Expression in Adenoid Cystic Carcinoma of the Skull Base

Timothy D. Doerr, MD; Lawrence J. Marentette, MD; Andrew Flint, MD; Victor Elner, MD, PhD

Arch Otolaryngol Head Neck Surg. 2003;129:215-218.

Background  Head and neck adenoid cystic carcinoma (ACC) is a malignancy of the salivary and lacrimal glands with a variable growth pattern and propensity for perineural spread. Involvement of the skull base indicates a poor prognosis. Despite surgical resection and adjuvant radiotherapy, tumor recurrence and metastases are common. The urokinase-type plasminogen activator and its receptor (uPAR) have an important role in tumor invasion and metastasis. The expression of uPAR is predictive of poor outcomes in many tumors. This study examines the expression of human uPAR in ACCs involving the skull base.

Objectives  To determine uPAR expression in ACCs of the skull base by immunohistochemical analysis and compare expression with tumor histologic findings and clinical outcomes.

Study Design  Analysis of uPAR in archival ACC specimens and a retrospective medical chart review.

Setting  Multidisciplinary cranial base program at a university medical center with tertiary referral pattern.

Results  Ten (83%) of 12 tumors stained positive for uPAR. Three of 3 patients who died of ACC and 6 of 6 patients alive with disease expressed uPAR. Only 1 of 3 patients free of disease was uPAR positive.

Conclusions  In most patients with ACC of the skull base, uPAR was expressed. Its expression seems to be a negative prognostic factor. However, the small study sample limits our observations. Additional study of uPAR expression in ACC at other anatomic sites is required.


From the Division of Otolaryngology–Head and Neck Surgery, University of Rochester School of Medicine and Dentistry, Rochester, NY (Dr Doerr); and Cranial Base Program, Department of Otolaryngology–Head and Neck Surgery (Dr Marentette), Department of Anatomic Pathology (Drs Flint and Elner), and Division of Occuloplastic Surgery, Department of Ophthalmology (Dr Elner), University of Michigan Medical Center, Ann Arbor.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Down-Regulation of Overexpressed Sp1 Protein in Human Fibrosarcoma Cell Lines Inhibits Tumor Formation
Lou et al.
Cancer Res. 2005;65:1007-1017.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.